Switching from Reference to Biosimilar Adalimumab for Patients with Various Inflammatory Conditions


( Last Updated : February 16, 2021)
Project Line:
Reference List
Project Sub Line:
Summary of Abstracts
Project Number:
RB1552-000

Details


Question


  1. What is the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, or uveitis?

  2. What is the clinical effectiveness of switching from reference to biosimilar adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis?


Key Message

Ten randomized controlled trials and 4 non-randomized studies were identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, or psoriatic arthritis. No evidence was identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with uveitis or ankylosing spondylitis and in pediatric patients with polyarticular juvenile idiopathic arthritis.